Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#OBJECT> ?p ?o ?g. }
- OBJECT label "antibody" assertion.
- OBJECT label "antibody" assertion.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label "during the COVID-19 pandemic" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label ""anti-allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.